Healthcare - Biotechnology - NASDAQ - US
$ 41.96
-8.67 %
$ 2.72 B
Market Cap
-19.61
P/E
BALANCE SHEET
576 M
ASSETS
181 M
LIABILITIES
395 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Kymera Therapeutics, Inc.
| Current Assets | 405 M |
| Cash & Short-Term Investments | 375 M |
| Receivables | 18.8 M |
| Other Current Assets | 11.7 M |
| Non-Current Assets | 170 M |
| Long-Term Investments | 61.4 M |
| PP&E | 101 M |
| Other Non-Current Assets | 7.93 M |
| Current Liabilities | 85.7 M |
| Accounts Payable | 7.08 M |
| Short-Term Debt | 12.7 M |
| Other Current Liabilities | 65.9 M |
| Non-Current Liabilities | 95.1 M |
| Long-Term Debt | 157 M |
| Other Non-Current Liabilities | -61.6 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Cash & Cash Equivalents | 110.0 | 68.4 | 48.0 | 31.0 | 76.0 | 41.3 |
| Short Term Investments | 264.9 | 338.8 | 394.4 | 265.2 | 15.9 | 0 |
| Receivables | 18.8 | 2.5 | 0.1 | 1.4 | 0 | 0.1 |
| Inventory | 0 | (12.2) | (9.0) | (163.4) | 0 | 0 |
| Other Current Assets | 11.7 | 9.7 | 8.7 | 4.7 | 0.9 | 0.4 |
| Total Current Assets | 405.3 | 559.5 | 567.6 | 302.3 | 92.8 | 41.8 |
| PP&E | 101.1 | 13.3 | 11.9 | 10.8 | 22.1 | 2.2 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 61.4 | 152.3 | 125.2 | 162.5 | 1.8 | 0.2 |
| Other Long Term Assets | 7.9 | (122.0) | (98.8) | 11.5 | 0 | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 575.8 | 603.1 | 605.9 | 487.2 | 116.7 | 44.2 |
| LIABILITIES | ||||||
| Accounts Payable | 7.1 | 4.3 | 4.0 | 4.4 | 3.3 | 2.1 |
| Short Term Debt | 12.7 | 7.9 | 7.2 | 6.5 | 3.4 | 0.3 |
| Other Current Liabilities | 28.0 | 23.9 | 19.6 | 7.2 | 4.6 | 2.3 |
| Total Current Liabilities | 85.7 | 63.3 | 101.0 | 110.6 | 34.6 | 4.7 |
| Long Term Debt | 156.7 | 26.8 | 28.7 | 29.5 | 17.8 | 0.4 |
| Deferred Tax Income | 0 | 0 | (53.7) | 0 | 0 | 0 |
| Other Liabilities | (78.3) | (13.1) | (14.3) | (14.6) | 109.1 | 73.6 |
| Total Liabilities | 180.8 | 113.0 | 146.3 | 203.3 | 191.1 | 78.7 |
| EQUITY | ||||||
| Common Stock | 6 K | 6 K | 5 K | 4 K | 0 | 0 |
| Retained Earnings | (530.8) | (383.8) | (229.0) | (128.8) | (76.5) | (35.2) |
| Other Accumulative Comprehensive Income/Loss | (0.6) | (4.9) | (0.7) | (0.1) | 6 K | 0 |
| Total Equity | 395.0 | 490.2 | 459.6 | 283.9 | (74.4) | (34.4) |
| Total Liabilities and Equity | 575.8 | 603.1 | 605.9 | 487.2 | 116.7 | 44.2 |
| SHARES OUTSTANDING | ||||||
| Common Shares Outstanding | 58.4 | 53.9 | 48.0 | 17.3 | 44.5 | 44.5 |